Lifeline Scientific, Inc Grant of options (1696E)
May 07 2013 - 11:56AM
UK Regulatory
TIDMLSI
RNS Number : 1696E
Lifeline Scientific, Inc
07 May 2013
Wednesday 7 May 2013
Lifeline Scientific, Inc.
("Lifeline" or "the Company")
Grant of options
Lifeline Scientific, the medical technology company focused on
the worldwide commercialization of its LifePort Kidney transporter,
a product designed to address the global challenge of human donor
organ shortages, announces that on 3 May 2013 it granted a total of
219,000 options over common shares with an exercise price of
GBPGBP1.90. The options vest over the first 4 years from the date
of issue, being 3 May 2013, at a rate of 25 per cent. per annum and
are exercisable for a period of 10 years.
Included in that grant of options are the following options
awards to members of the Board and senior management:
3 May grant
--------------- ------------
David Kravitz 85,000
--------------- ------------
Lisa Kieres 25,000
--------------- ------------
John Garcia 1,750
--------------- ------------
Andrew Clark 1,500
--------------- ------------
Klaas de Boer 10,000
--------------- ------------
Steven Mayer 1,500
--------------- ------------
Eric Swenden 1,500
--------------- ------------
For further information:
Lifeline Scientific, Inc. Tel: +1 847-294-0300
David Kravitz, CEO
Panmure Gordon (UK) Limited Tel: +44 20 7886 2500
Freddy Crossley / Fred Walsh. (Corporate
Finance)
Adam Pollock / Victoria Boxall (Corporate
Broking)
FTI Consulting Tel: +44 20 7831 3113
Simon Conway / John Dineen
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to provide improved kidney preservation, evaluation and
transport prior to transplantation. Today, it is widely recognised
as the world's leading machine preservation device for kidneys.
Employed by surgeons in over 135 leading transplant programmes in
23 countries worldwide, LifePorts have successfully preserved over
38,000 kidneys intended for clinical transplant. The product
provides a sealed, sterile, protected environment where a solution
is gently pumped through the kidney at cold temperatures to
minimise damage while the organ is outside the body. LifePort is
lightweight and portable, allowing organs to be perfused from the
time of recovery until transplant. It is designed to travel
unaccompanied by land or air, safely transporting the kidneys
across town or between countries. While the kidney is being
perfused, LifePort records data on temperature, flow rate, vascular
resistance and pressure every 10 seconds providing surgeons with
additional data prior to transplant. LifePort is the only system
with clinical outcomes data produced from an independent,
prospective, randomised, statistically powered, multi-centre
clinical trial. Study results have been widely published in
scientific journals, including the New England Journal of Medicine.
Data indicates that patients receiving LifePort preserved kidneys
experienced significant reduction in the incidence and duration of
delayed graft function and increased graft survival at 1-year and
3-years post transplant. LifePort has also been recognised for its
design and engineering. It has received prominent awards for design
excellence from the medical device industry, has been selected for
exhibition at the Smithsonian Cooper-Hewitt, National Design Museum
and is part of the permanent Collection of The Museum of Modern Art
(MoMA) in New York City.
About Lifeline Scientific, Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product is the FDA cleared, CE marked and
clinically validated LifePort Kidney Transporter. Devices for
preservation of the liver, pancreas, heart, and lung are in late
stage pre-clinical development.
See www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEDLFBXEFEBBZ
Lifeline Sci. S (LSE:LSI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lifeline Sci. S (LSE:LSI)
Historical Stock Chart
From Aug 2023 to Aug 2024